Singapore markets closed

Cellectis S.A. (CLLS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.72000.0000 (0.00%)
At close: 03:59PM EST
2.6100 -0.12 (-4.40%)
Pre-market: 05:21AM EST
Full screen
Trade prices are not sourced from all markets
Previous close2.7200
Open2.6000
Bid0.0000 x 900
Ask0.0000 x 1100
Day's range2.6000 - 2.7750
52-week range0.9630 - 3.7740
Volume61,851
Avg. volume80,415
Market cap194.708M
Beta (5Y monthly)3.14
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Insider Monkey

    Cellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call Transcript

    Cellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good morning, everyone, and welcome to the Cellectis Third Quarter 2023 Earnings Calls. [Operator Instructions]. I’d now like to introduce the first speaker Arthur Stril, Chief Business Officer. You may begin. Arthur Stril: Good morning, and welcome, everyone, to Cellectis third quarter 2023 […]

  • Reuters

    AstraZeneca to invest $245 million in Cellectis to boost gene therapy prospects

    Cellectis' gene-editing technology and manufacturing capabilities to design novel cell and gene therapy products will help strengthen AstraZeneca's growing offering in the space, it said. AstraZeneca said that as part of the deal, it will pay Cellectis $105 million by the end of this year. That includes an $80 million equity investment, which will be followed by another $140 million in early 2024, which will give AstraZeneca a stake of about 44% in the French company.